3-Thiometaescaline
 | |
| Clinical data | |
|---|---|
| Other names | 3-TME; 3-Ethylthio-4,5-dimethoxyphenethylamine; 4,5-Dimethoxy-3-ethylthiophenethylamine; 3-EtS-4-MeO-5-MeO-PEA |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | "Quite early"[1] |
| Duration of action | 10–15 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H19NO2S |
| Molar mass | 241.35 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Thiometaescaline (3-TME), also known as 3-ethylthio-4,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3][4] It is the analogue of metaescaline in which the ethoxy group at the 3 position has been replaced with an ethylthio group.[1][2][3][4] The drug is one of three possible positional isomers of thiometaescaline (TME), the others being 4-thiometaescaline (4-TME) and 5-thiometaescaline (5-TME).[1][2][3][4]
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 3-TME's dose as 60 to 100 mg orally and its duration as 10 to 15 hours.[1][2][3] Its onset is "quite early" and substantial effects occur by 1.5 hours.[1] The drug is approximately 4 to 6 times as potent as mescaline.[2][3][4] The effects of 3-TME have been reported to include introspection and insights, disinhibition, easy humor, sleep disturbances, and increased psychological strength after the experience.[1] One person reported it as producing a "remarkable state" and another remarked that it was a kind of experience that should be had once a year if not more often.[1] No visual or other perceptual effects were mentioned.[1]
The chemical synthesis of 3-TME has been described.[1][4]
3-TME was first described in the scientific literature by Alexander Shulgin and Peyton Jacob III in 1984.[4] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1]
See also
References
- ^ a b c d e f g h i j k l m Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. https://www.erowid.org/library/books_online/pihkal/pihkal163.shtml
- ^ a b c d e Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID 8742795. Archived from the original on 13 July 2025.
- ^ a b c d e Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
- ^ a b c d e f Jacob P, Shulgin AT (July 1984). "Sulfur analogues of psychotomimetic agents. 3. Ethyl homologues of mescaline and their monothio analogues". J Med Chem. 27 (7): 881–888. doi:10.1021/jm00373a013. PMID 6737431.